Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Acalisib
Synonyms
Therapy Description

Acalisib (GS-9820) is a selective PI3K-delta inhibitor that may affect cell survival and differentiation (PMID: 24133210).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Acalisib GS-9820|CAL-120 PIK3CD inhibitor 25 Acalisib (GS-9820) is a selective PI3K-delta inhibitor that may affect cell survival and differentiation (PMID: 24133210, PMID: 29434192).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown hematologic cancer not applicable Acalisib Phase I Actionable In a Phase Ib trial, Acalisib (GS-9820) treatment resulted in lymph node reduction in 70% (7/10) and nodal partial response in 40% (4/10) of patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia (Blood: 122 (21): 2881). detail...
PIK3CA mutant breast adenocarcinoma sensitive Acalisib Preclinical - Cell line xenograft Actionable In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of breast adenocarcinoma harboring a PIK3CA mutation (Mol Cancer Ther 2009;8(12 Suppl):B136). detail...
Unknown unknown ovary adenocarcinoma not applicable Acalisib Preclinical - Cell line xenograft Actionable In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of ovarian adenocarcinoma (Mol Cancer Ther 2009;8(12 Suppl):B136). detail...
Unknown unknown non-Hodgkin lymphoma not applicable Acalisib Phase Ib/II Actionable In a Phase Ib trial, Acalisib (GS-9820) treatment resulted in an overall response rate of 28.6% (4/14), with 4 partial responses, stable disease in 3 patients, and a lymph node response in 36.4% (4/11) of patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma (PMID: 29434192; NCT01705847). 29434192
Unknown unknown chronic lymphocytic leukemia not applicable Acalisib Phase Ib/II Actionable In a Phase Ib trial, Acalisib (GS-9820) treatment resulted in an overall response rate of 53.3% (8/15), with 8 partial responses, stable disease in 6 patients, and a lymph node response in 85.7% (12/14) of patients with chronic lymphocytic leukemia (PMID: 29434192; NCT01705847). 29434192

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status


Additional content available in CKB BOOST